NVO · Novo Nordisk A S
Price & Indicators
Up next
Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVO
this stock
Novo Nordisk A S
|
$228.21B | -4.1% | — | — | 0.7% |
|
LLY
ELI LILLY & Co
|
$1.08T | +7.1% | +44.7% | 40.8 | 1.1% |
|
JNJ
Johnson & Johnson
|
$616.50B | +24.5% | +6.0% | 29.7 | 1.1% |
|
ABBV
AbbVie Inc.
|
$454.79B | +10.7% | +8.6% | 126.8 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$320.56B | +25.5% | +1.4% | 36.6 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVO | -3.5% | -6.6% | +2.5% | -1.8% | -4.1% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | -4.6% | -6.9% | -5.7% | -1.8% | -13.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.